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1. Introduction
Hepatocellular carcinoma (HCC) is among the most common malignancy and cause of can‐
cer related death worldwide, with a high prevalence in Asia and south Africa as well as an
increasing incidence in the western country. Patients with liver cirrhosis are at highest risk
of developing this malignant disease, and the majority of HCC patients will develop the dis‐
ease on the background of preexisting hepatitis virus infection. It is estimated 50–70% asso‐
ciated with hepatitis C virus in North America and Europe and 70% associated with
hepatitis B virus in Asia and Africa [1], and the incidence of HCC is significantly higher in
men than in women. However, surveillance programs for HCC in patients with cirrhosis
and chronic hepatitis, and the advancement of diagnostic tools are likely to further increase
the incidence of HCC and the detection of small lesions in the liver that prompted the pro‐
portion of patients diagnosed at a potentially curative stage of disease.
Several staging systems have so far been proposed for aiding assessment of treatment plan‐
ning for HCC patients, but an overall consensus remains not exist for any of these staging
systems.The Tumor-Node-Metastasis staging (TNM) system of the American Joint Commit‐
tee on Cancer/Committee of the International Union Against Cancer (AJCC/UICC) has been
widely used for numerous cancer staging in order to stratify patients into prognostic groups
[2], but it is not perfectly applicable for HCC in terms of treatment assessment as the TNM
staging does not consider the underlying liver functional reserve and seems only applicable
to patients undergoing liver resection or liver transplantation. The Cancer of the Liver Ital‐
ian Program (CLIP) classifications and the Okuda staging system were introduced not only
considering tumor features but also liver functional reserve.The CLIP scoring system con‐
siders cirrhotic status in terms of Child-Turcotte-Pugh (CTP) class and several factors relat‐
ed to tumor features including tumor morphology, Alphafeto protein (AFP) level, and
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portal vein thrombosis [3]. Although the CLIP scoring system is probably helpful to identify
patients with a poor prognosis, it might be inadequate to identify patients at early stages of
disease. The Okuda system has also been found unsuitable for prognostic stratification of
patients at an early stage of disease [4]. Therefore, the Japan Integrated Staging score that
combines the CTP class with the Liver Cancer Study Group of Japan TNM stage was formu‐
lated to provide better stratification of patients with early HCC than that achieved by the
CLIP score and Okuda system [5]. Additionally, the Barcelona Clinic Liver Cancer(BCLC)
staging system was suggested as a modification of the Okuda system, and has been validat‐
ed superior for prognostic stratification of patients with HCC than other staging systems
[6-8]. The BCLC staging system involves factors related to underlying liver function, tumor
characteristics, and patients' performance status, and was proposed as a means of predicting
prognosis and as a guide to selecting appropriate therapy for HCC patients.
Generally, these staging systems was developed aiming to stratify patients into groups with
similar prognoses and to serve as a guiding choice of therapy. Current popular treatments
for HCC include liver resection, percutaneous ethanol injection (PEI) or radiofrequency
ablation (RFA), transcatheter arterial chemoembolization (TACE), liver transplantation, and
targeted therapy with novel biologic agent such as sorafenib. The selection of treatment mo‐
dality for HCC patients should be based on the patient's prognosis, which is complex to as‐
sess, as it depends on three factors, namely, the tumor characteristics, the underlying liver
functional reserve and the patient’s physical condition. At present, only liver resection and
liver transplantation are considered the best potential curative therapies. Nonetheless, be‐
cause of underlying liver dysfunction, lack of liver donor availability, and/or late detection
at advanced cancerous stage, only a small proportion of patients are eligible for these cura‐
tive treatments. This chapter reviews the importance and clinical impact of surgical manage‐
ment in terms of liver resection and transplantation for patients with primary HCC and
highlights their relative strengths and weakness.
2. Liver Resection
Liver resection remains the mainstay curative treatment for patients with HCC. However,
the majority of HCC patients are often associated with liver cirrhosis due to hepatitis B or C
viral infection, which might prohibit from liver resection because of impaired liver function.
Moreover, many HCC patients present with advanced tumor stage and only approximately
20–30% of patients are candidates for liver resection on presentation [9-11]. In spite of this
situation, the advancement in anesthetic and surgical techniques, as well as a thorough un‐
derstanding of the liver anatomy, and better perioperative care, have contributed dramati‐
cally to the safety and effectiveness of liver resection for HCC.
Since the proposal of the finger fracture technique for hepatic lobectomy in 1953, transection
of the hepatic parenchyma has evolved during the last 50 years. By finger fracture techni‐
que, the liver tissue is fractured and crushed by the thumb and index finger followed by
isolating and ligating the resistant intrahepatic vascular and ductal structures [12]. Howev‐
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er, there is some troublesome bleeding from the resection line which makes the surgeons fear
for the safety of the finger fracture technique. To overcome this short coming of the finger
fracture technique, many special instruments were invented to increase the successful rate and
safety of liver resection ever since (Figure 1). Currently, Kelly clamp crushing technique is still
one of the most widely used techniques for liver resection. However, in many centers, includ‐
ing the author’s center, ultrasonic dissection using the Cavitron Ultrasonic Surgical Aspira‐
tor (CUSA) has become the standard technique of liver resection. Today, laparoscopic liver
resection has become feasible in experienced centers due to improvement in instruments
[13-15]. Additionally, modern concepts including the use of vascular inflow occlusion, ana‐
tomic resection, and low central venous pressure anesthesia, and surgical approaches such as
the anterior approach and liver hanging maneuver have been developed along with using
more effective instruments for transection of hepatic parenchyma [16-18]. As a result, liver
resections are increasingly being performed and accepted as a safety procedure.
Figure 1. Liver resection instruments. (a). Lin’s clamp designed by T.Y. Lin. (b). Kelly clamp. (c). Cavitron Ultrasonic Sur‐
gical Aspirator (CUSA). (d). Harmonic scalpel for laparoscopic liver resection.
2.1. Preoperative assessment
The major concern of liver resection in HCC patients is postoperative liver failure, which is
particularly worrisome in patients requiring major resections and/or diseased background
of cirrhotic liver. Therefore, a thorough evaluating of patients in terms of tumor features of
radiologic examination, underlying liver function, and the patient’s physical status is very
important. Theoretically, a successful liver resection for HCC patients should be weighed
against the balance of these three factors.
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2.1.1. Evaluation of tumor status
The assessment of tumor status is the essential step for determining resectability and the ap‐
propriate type of liver resection. The routine radiologic imaging examination prior to liver
resection should include a dynamic liver computed tomography (CT) scan, hepatic angiog‐
raphy, and/or magnetic resonance imaging (MRI) to confirm the diagnosis of HCC as well as
tumor status in terms of size, number and location. Additionally, a chest X-ray or contrast
CT scan of chest and abdomen could be performed to exclude lung or other extrahepatic
metastasis. The CT scan provides important information not only on the tumor size, num‐
ber, location, and any vascular invasion but also on the relationship between the tumor and
major vasculature. Generally, pre-operative biopsy is not necessary as may risk needle track
related tumor seeding.
Large HCC—Solitary HCC with diameter of less than 5 cm is the best candidate for liver re‐
section because of favorable patients’ outcome in terms of HCC recurrent-free survival [19,
20]. However, numerous patients continue to be diagnosed HCC at an advanced stage that
sometimes presented with large tumor with diameter exceed 10 cm. Although liver resec‐
tion for patients with large tumor can be a great challenge for liver surgeons, liver resection
for large HCCs has been shown to be safe and reasonable long-term survival results can be
achieved that appear to be much better than any other nonsurgical treatments [21-23]. The 5-
year survival rate in patients with tumors larger than 10 cm after liver resection is approxi‐
mately 21–27.5% [23-25]. Additionally, since liver transplantation and local ablation are not
indicated for these patients, surgical resection remains the only treatment of choice that pro‐
vides potential cure of patients with large HCC.
Multiple HCCs—Multiple HCCs may represent as a manifestation of advanced disease with
intrahepatic metastasis or independent tumors that derived from multiple foci of hepatocar‐
cinogenesis, which could be an event associated with a poor prognosis. Patients with multi‐
ple HCCs more than 3 nodules have been considered unsuitable for resection. However, it
had been shown that liver resection still can provide survival benefits even for patients with
multiple tumors in a background of CTP class A cirrhosis, and the overall survival rates can
up to 58% at 5 years [26]. Additionally, combined resection and radiofrequency ablation is
considered a new strategy to increase the chance of curative treatment for patients with bilo‐
bar multiple HCCs. For example, resection of the large tumor in one lobe and ablation of
smaller tumors in the other lobe can be performed, or resection of peripheral lesions and
ablation of central lesions for patients with multifocal tumors associated with cirrhosis and
borderline liver function can be performed [27, 28]. The results showed patients who under‐
went surgical resection for multiple HCCs had better survival outcomes as compared with
those who received nonsurgical therapy. Hence, when clearance of all tumor nodules is fea‐
sible and liver function permits, surgical resection or plus effective local ablative therapy
should be considered for patients with bilobar or multiple HCCs.
HCC involving major portal and hepatic veins—HCCs with major portal or hepatic veins in‐
volvement represent an aggressive tumor behavior and frequently associated with multifo‐
cal tumors. Although HCCs with vascular invasion are not considered as favorable surgical
candidates, studies from experienced liver surgical groups have shown that surgical resec‐
Hepatic Surgery304
tion for such tumors seems justified as it still results in better survival rates as compared
with that of nonsurgical treatment [29, 30]. The overall survival rates at 5 years were ranged
from 23% to 42% in selected patient who has no liver cirrhosis or impaired liver function.
2.1.2. Evaluation of liver function
Preoperative proper assessment of liver function is fundamental to the safe of liver resection
for HCC patients, but there is no individual test accurately predicting liver function.The
CTP classification is the most common measure to assess liver function, and it combines dif‐
ferent parameters and provides a rough evaluation of the gross synthetic and excretory ca‐
pacity of the liver. Generally, patients with CTP class A are considered good candidates for
liver resection. Patients with CTP class B may be only suitable for minor liver resection such
as wedge resection or single segmentectomy [31], whereas patients with CTP class C are
contraindicated for resection. The risk of death after liver resection increases with each CTP
class. However, this classification is a crude measure and has proven insufficient to stratify
the surgical risk of patient with liver cirrhosis.
Portal hypertension is usually defined by that the portal venous pressure is greater than 10
mmHg, in which the normal value ranges from 5 to 8 mmHg. Patients with portal hyperten‐
sion undergoing liver resection may lead to severe complications, such as variceal bleeding,
endotoxemia, and even hepatic failure in the postoperative period [32]. However, measure‐
ment of portal venous pressure prior to liver resection is difficult, and portal hypertension
could only be roughly assessed by clinical and radiologic signs including splenomegaly, ab‐
dominal collaterals, thrombocytopenia with platelet count less than 100,000/mm3, or esopha‐
gogastric varices. Although portal hypertension is considered a relatively contraindication
of liver resection, study had shown that liver resection is also capable of providing survival
benefits to patients with a background of portal hypertension [26]. Additionally, patients
with abnormal elevation of liver function tests in terms of serum aspartate and alanine ami‐
notransferase levels might have a higher risk of postoperative complication and mortality
rates, and are considered to be poor candidates for major liver resection [33, 34]. Therefore,
patients with abnormal liver function tests should be carefully assessed and selected prior to
liver resection.
Additionally, several hepatobiliary centers have employed more sophisticated quantitative
liver function tests, such as the lidocaine monoethylglycinexylidide test, aminopyrine breath
test, galactose elimination capacity, and indocyanine green (ICG) clearance test to evaluate
the hepatic metabolic function and to predict the risk of postoperative liver failure [35-37].
However, these specific tests reflect the function of the whole liver, whereas the risk of post‐
operative liver failure relies on the liver function reserve of the remnant liver. Among the
various methods, the ICG test is the most widely used to assess liver function prior to liver
resection. The ICG is an organic dye that is taken up by the hepatocytes and excreted via the
bile in an adenosine triphosphate (ATP) dependent manner without been metabolized and
undergoing enterohepatic circulation. Thus, the clearance of ICG from systemic circulation
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is merely a measure of hepatic blood flow and function. This test evaluates the retention ra‐
tio of ICG from the peripheral blood at definitive time point after injection of 0.5 mg ICG/kg
(usually 15 minutes, ICG-15), and Makuuchi et al. have incorporated the ICG-15 and two
clinical features in terms of serum bilirubin level and the presence of ascites into an algo‐
rithm of liver resection (Figure 2) [38]. In patients with bilirubin levels less than 1.0mg/dL
and the absence of ascites, ICG-15 is used to predict the extent of liver segments that can be
safely removed. In general, an ICG-15 of 10–20% is usually considered a safety upper limit
for major liver resection. Accordingly, the algorithm has been validated toward zero surgi‐
cal mortality after liver resection by several hepatobiliary centers [39, 40].
Figure 2. Makuuchi’s algorithm for liver resection in patients with HCC [38]. Limited resection means enucleation of
the tumor (usually ≤ 5cm) and less than 1 cm of liver tissue surrounding the tumor was removed.
ICG-15 (%) Safe resection ratio of liver volume
0 < 63.3%
~ 5 < 53.4%
~ 10 <43.5%
~ 15 <33.6%
~ 20 <23.7%
~ 25 <13.8%
~ 30 <3.9%
≥ 32 0%
Table 1. The safe resection ratio of liver volume based on the ICG test [43].
Although the assessment of hepatic function and liver volume to be resected is crucial for a
safe liver resection, volumetric analysis of the future liver remnant (FLR) has also been sug‐
gested. The FLR can be measured directly by computer-assisted models of contrast-en‐
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hanced spiral CT. However, it remains controversial regarding which index of the FLR
volume should be used. Some surgeons use the actual total liver volume minus liver volume
to be removed on CT images as the FLR volume, while others use the estimated ideal liver
volume that is calculated by a formula based on body surface area as a standard for calcula‐
tion of the FLR. Nonetheless, the exactly number of the adequate FLR volume in cirrhotic
patients is also no consensus, and at least an FLR of 40% is recommended in patients with
chronic liver disease [41, 42]. In the authors’ center, we have established an equation to re‐
veal the relationship between the ratio of FLR volume and ICG-15 values as well as referen‐
ces for determining a safe resection ratio of the liver volume (Table 1)[43].
2.2. Preoperative therapy
Since not all patients with HCC are amenable to surgical resection, several strategies such as
preoperative TACE that might be used to downsize large HCC or portal vein embolization
(PVE) to increase the FLR have been suggested. However, the efficacy of these preoperative
approaches in terms of HCC oncologic viewpoint remains the subject of debate.
2.2.1. Portal vein embolization
The concept of PVE was introduced on the basis of the idea that an increase in the FLR will
reduce the risk of liver failure after major liver resection for hilar bile duct carcinoma in 1982
[44]. By occluding portal venous branch of the tumor-bearing liver, PVE induces atrophy of
the resection part and hypertrophy of the FLR. Although the ability of liver regeneration in
cirrhotic liver is impaired, PVE may induce clinically sufficient hypertrophy in these pa‐
tients as well.Currently, PVE could be considered for patients with liver cirrhosis when the
FLR is expected less than 40% of the total liver volume [45, 46]. PVE may also be used as a
dynamic liver function test, in which inadequate hypertrophy of the FLR or intolerance of
the patient after PVE indicate that major liver resection is contraindicated. In general, PVE is
a relatively safe procedure, and it may increase the resectability of initial unresectable HCC
and reduce the risk of post hepatectomy liver failure. Additionally, it seems no adverse ef‐
fect on the oncologic outcome of HCC patients undergoing major liver resection [47, 48].
However, the potential for progression of the primary tumor after PVE remains a major con‐
cern, whereas a combination of TACE as a complementary procedure to PVE could be con‐
sidered in order to improve the outcome of HCC patients [49].
2.2.2. Preoperative transcatheter arterial chemoembolization (TACE)
The use of TACE as a neoadjuvant treatment for HCC was proposed in a variety of settings
such as palliative treatment for unresectable HCC, to improve the resectability of intial unre‐
sectable HCC, to downstage the primary tumor for liver transplantation or for delay sur‐
gery. The major goal of TACE is aimed at inducing tumor necrosis and shrinkage as well as
preventing the dissemination of the primary tumor (Figure 3). Theroretically, the use of neo‐
adjuvant TACE in the setting of resectable HCC might be capable of improving survival by
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reducing tummor recurrences. Nonethelesss, the fact is that most studies show conflict out‐
comes of TACE as a neoadjuvant therapy and do not support routine use of preoperative
TACE before liver resection [50-53]. Moreover, preoperative TACE for resectable large HCC
is not recommended because it does not provide complete necrosis of the large tumor and‐
may actually result in progression of the primary tumor owing to delay surgery and compli‐
cate the operation during the process of liver mobilization due to the presence of perihepatic
adhesions after TACE.
Figure 3. TACE induces remarkable shrinkage of tumor mass. (a) A huge liver tumor around 15 cm in size located at
right lobe liver. (b) The tumor was decreased by half in size after three courses of TACE. (4 months after HCC diag‐
nosed)
Clinically, spontaneous tumor rupture accompanied by hemorrhaging has been seen in
small portion of patients with HCC at initial presentation, which might lead to a life-threat‐
ening condition depending on the severity of hemorrhage. Transcatheter arterial emboliza‐
tion (TAE) should be performed for ruptured HCC to control tumor bleeding as well as
stabilizing clinical condition of patients. Liver resection then can be evaluated after the pa‐
tient has recovery from shock status and post-TAE damage of the liver according to the cri‐
teria of liver resection. Generally, TAE followed by staged liver resection of tumor seems to
be a rational treatment strategy for patients with ruptured HCC and hemorrhage if the le‐
sion is resectable, and long-term survival could be expected [54, 55].
2.3. Outcome of liver resection
The operative mortality of liver resection has been reduced to less than 5% with some cen‐
ters approaching to zero mortality in recent years [39, 40, 56]. The improvement is primarily
resulting from advances in surgical techniques, perioperative management, and more cau‐
tious patient selection. However, the postoperative morbidity rate remains high that ranges
from 25 to 50% even in experienced centers [11, 57, 58]. Ascites and pulmonary complica‐
tions are the most common complications, but serious complications such as liver failure,
postoperative hemorrhage, bile leakage, and intra-abdominal sepsis are less frequent nowa‐
days. Apart from that, the long-term survival after resection of HCC have much improved‐
lately, but HCC recurrence remains a major concern for patients undergoing liver resection.
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2.3.1. HCC recurrence
The high incidence of postoperative recurrence, estimated excess of 70% at 5 years, is the
greatest frustration in treating patient with HCC. Recurrent HCCs are mostly intrahepatic
that accounts for approximately 80–90% of cases after liver resection. There are two peaks of
HCC recurrence after liver resection:The first peak occurs at approximately 1 year posthepa‐
tectomy and about 40% of recurrence within the period, in which metastatic dissemination
of the primary tumor is mainly responsible for this early peak. The second peak is observed
at the 4th postoperative year with a 35% of recurrent rate per year, and the majority of the
second peak is more likely attributable to new tumors development related to the carcino‐
genic effect of underlying chronic liver disease [59].
Currently, there is no well-established adjuvant therapy to reduce the risk of recurrence af‐
ter curative liver resection. Although numerous studies have demonstrated the efficacy of
some new modalities including acyclic retinoid, polyprenoic acid [60], intra-arterial io‐
dine-131-labelled lipiodol [61], and adoptive immunotherapy [62] as adjuvant therapy in the
prevention of HCC recurrence after liver resection, the sample size of these individual stud‐
ies was rather small and further validated by randomized trials with large sample size is re‐
quired. Additionally, interferon has been proposed as adjuvant therapy in patients with
HCC and viral hepatitis after liver resection and shown beneficial for reducing recurrence
and prolonging survival [63, 64]. Nonetheless, a more recent cohort study based on a phase
III randomized trial of adjuvant interferon alfa-2b in HCC after curative resection does not
support the benefit of interferon in reducing postoperative recurrence of viral hepatitis-re‐
lated HCC [65]. Apart from that, another potential approach is to use molecular targeted
therapy such as sorafenib that is applied for advanced HCC and may inhibit HCC cell pro‐
liferation and angiogenesis. However, further trial is indicated to test the efficacy of these
targeting drugs as adjuvant therapy after resection of HCC.
Compared with the development of  postoperative adjuvant  therapy,  the risk factors  for
HCC recurrence after liver resection have been extensively explored and established. The
risk factors for tumor recurrence can be categorized into three core groups, related to host
factors, tumor factors, and surgical factors [66].  The tumor factors including vascular in‐
vasion,  satellite  nodules,  large  tumor,  elevation  of  AFP,  poor  differentiated  histologic
grade,  tumor rupture,  and advanced tumor stage are frequently reported risk factor  for
HCC recurrence after liver resection. The host factors are the patient’s characteristics and
underlying liver diseases such as cirrhosis and viral  hepatitis.  Both tumor and host fac‐
tors  are  determined before  operation,  and the  surgeon can only  control  surgical  factors
including  negative  resection  margin,  anatomic  resection,  meticulous  liver  mobilization,
and less blood transfusion.
The treatment strategy for HCC recurrence after liver resection should be the same as that
for primary HCC. Although repeat hepatectomy could be a difficulty owing to perihepatic
adhesion related to first operation, surgical resection remains a preferred treatment whenev‐
er the tumor is considered to be resectable [67-69].
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2.3.2. Survival of patients
Despite the high incidence of postoperative HCC recurrence, current strategy of aggressive
multimodality treatments for recurrent tumors using TACE, RFA, or liver transplantation
has largely improved the overall outcomes of patients even after the development of recur‐
rent HCC. Moreover, surgical resection of recurrent HCC presenting as extrahepatic meta‐
stases could be considered in selected patients who are with isolated extrahepatic metastases
and has otherwise good performance status, good hepatic functional reserve, and well-treat‐
ed intrahepatic HCC, and a survival benefit can be expected from this aggressive approach
[70]. Generally, the overall 5-year survival after resection of HCC reported in the literature
from large series is mostly near 50% or even better in recent years (Table 2).
Authors (Years) Study period Subgroups No. of patients 5-year RFS/OS
Hanazaki et al. (2000) [71] 1983–1997 386 23.3%/34.4%
Zhou et al. (2001) [58] 1967–1998 size≤5cm
size>5cm
1000
1366
─/62.7%
─/37.1%
Wang et al. (2010) [72] 1991–2004 438 ─/43.3%
Fan et al. (2011) [73] 1989–2008 1989–1998
1999–2008
390
808
24%/42.1%
34.8%/54.8%
Sakamoto et al. (2011) [74] 1988–2010 Caudate lobe
Other sites
46
737
44%/76%
40%/64%
Nara et al. (2012) [75] 1990–2007 SM>1mm
SM≤1mm
SM-postive
374
165
31
40.0%/72.2%
28.1%/63.5%
7.4%/36%
Chan et al. (2012) [76] 2001–2005 651 33.9%/51.7%
Giuliante et al. (2012) [77] 1992–2008 Tumor ≤3cm 588 32.4%/52.8%
Shrager et al. (2012) [78] 1992–2008 Non-cirrhosis
cirrhosis
206
462
39%/46.3%
─/─
Altekruse et al. (2012) [79] 1998–2008 SEER–13 1348 ─/47%
Table 2. Long-term survival of patients undergoing liver resection for HCC reported from large series in recent years.
RFS, recurrence-free survival; OS, overall survival; SM, surgical margin; SEER-13, Surveillance Epidemiology and End
Results of USA.
3. Liver transplantation
Recurrence remains a major problem after liver resection for HCC even after margin-nega‐
tive resection. Most of the patients with HCC have underlying cirrhosis that provides poten‐
tial field for development of hepatocellular carcinoma. Since majority hepatic malignancies
are HCC and almost 80% of them have underlying cirrhosis, resection is option in only
Hepatic Surgery310
small number of patients and in such patients, recurrence rate is high after resection. Liver
transplantation practically offers greater chance of cure by removing underlying liver cir‐
rhosis and HCC. Also, HCC is multifocal especially with hepatitis C, and total hepatectomy
removes the source of potential possibility of later-developing tumors whereas partial hep‐
atic resection does not.
However, liver transplantation for HCC did not yield satisfactory results initially. Recur‐
rence rates were up to 80% and long term survival rates were unacceptably below that of
patients who underwent liver transplantation for non-malignant causes. These recurrences
usually appeared within 2 years of transplant, most common site being liver allograft that
led to a decline in enthusiasm and a serious concern about using precious donor livers for
treatment [80].It was Bismuth who initially reported good outcomes with liver transplanta‐
tion for small HCC [81] and subsequently, Mazzaferro et al introduced the Milan criteria re‐
porting liver transplantation for HCC with equivalent outcomes to non-HCC patients[82].
Liver transplantation has become now potential curative treatment and it is presently the
treatment of choice for patients with CTP class B or C cirrhosis and early hepatocellular car‐
cinoma. Compared with surgical resection, liver transplantation is associated with better
overall and recurrence-free survival in well selected patients [83-85]. The improved overall‐
results after liver transplantation are thought to be due to better patient selection and the
emergence of various locoregional therapies for HCC that prevent tumor progression while
patient is waitlisted for liver transplantation, thus preventing drop out.
3.1. Patient selection criteria
A major goal of liver transplant team is to select the patients with HCC and cirrhosis at earli‐
er stage of their disease in order to achieve survival duration comparable with that of other
patients with benign liver disease receiving transplants, so as to justify or prioritize the allo‐
cation of a liver graft. Liver transplant candidates with HCC must meet the Milan criteria to
qualify for exceptional HCC waiting list consideration. Also, several other extended criteria
such as UCSF (University of California at San Francisco) criteria are used for patient selec‐
tion in highly specialized transplant centres.
3.1.1. Milan’s criteria
In 1996, a prospective cohort study defined restrictive selection criteria that led to superior
survival for transplant patients in comparison with any other previous experience with
transplantation or other options for HCC. Since then, these selection criteria have become
universally known as the Milan criteria in recognition of their origin (Table 3) [82]. These
criteria have been widely applied in the selection of patients with HCC for liver transplanta‐
tion.In North America as well as in many other world regions, patients within Milan criteria
HCC are given priority to liver transplantation. Generally, a 4-year overall and recurrence-
free survival rates of 85% and 92%, respectively, can be achieved using this selection criteria.
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Criteria of liver transplantation for patients with HCC
Single lesion ≤5 cm.
Up to three separate lesions, none larger than 3 cm.
No evidence of gross vascular invasion.
No regional nodal or distant metastases.
Table 3. Milan’s criteria for liver transplantation.
3.1.2. Extended Criteria
Considerable interest has arisen in expansion of usual transplant criteria in highly special‐
ized centres to offer liver transplantation to broader group of patients with HCC as investi‐
gators argued that Milan’s criteria are too restrictive and limit liver transplantation at the
time when incidence of HCC is on the rise. Using explant pathologic data, Yao and co-work‐
ers at the University of California, San Francisco (UCSF) reported 5-year post-transplanta‐
tion survival of 75% in patients with tumors as large as 6.5 cm and cumulative tumor
burden ≤8 cm (Table 4)[86].
Extended criteria of liver transplantation for patients with HCC
Solitary tumor up to 6.5 cm.
A maximum of 3 tumor nodules each up to 4.5 cm.
A total tumor diameter not exceeding 8 cm.
No regional nodal or distant metastases.
Table 4. UCSF criteria for liver transplantation.
The UCSF criteria have been shown to be associated with long -term survival similar to Mi‐
lan criteria when based on explant pathology [87, 88]. However, because of the small sample
size and use of retrospective explant tumor pathology, the results of these studies were chal‐
lenged and also several groups advised caution in expanding the criteria.
Additionally, a recent multicentre study led by the Milan’s group had retrospectively re‐
viewed patients who underwent transplantation for HCC in order to explore the survival of
patients with tumors that exceed the Milan criteria. Accordingly, a prognostic model of
overall survival based on tumor characteristics in terms of size and number was derived,
and an expanded criterion termed “up-to-seven criteria” was introduced [89]. Patients who
fell within the criteria that the sum of the largest tumor size and the number of tumors does
not exceed seven could achieve a 5-year overall survival of 71.2% after liver transplantation
enabling more patients to qualify as transplant candidates.
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3.2. Prognostic Indicators
Several studies have identified patient and tumor-related variables associated with progno‐
sis following liver transplantation for HCC. The majority of prognostic factors are similar to
that of liver resection for patients with HCC.
3.2.1. Tumor related factors
Important prognostic factors in most of scientific studies include tumor number, size, and
location (especially bilobar distribution). The most consistent association is with tumor size.
Other factors are histologic grade of differentiation, stage of disease according to the Ameri‐
can Liver Tumor Study Group (ALTSG) modification of the TNM staging criteria, the pres‐
ence of macrovascular and microvascular invasion, absolute level of serum AFP, and
extrahepatic spread. Tumor size predicts both the likelihood of vascular invasion and tumor
grade, but the relationship is nonlinear and a significant proportion of small tumors have
unfavourable histology, whereas some larger ones do not [90, 91].
3.2.2. Patient related factors
Patients with HCV infection tend to have severe underlying liver disease and more ad‐
vanced HCC at presentation as compared to HBV infection and underlying alcoholic cirrho‐
sis. Hence, the recurrence of HCC is more common among the HCV recipients and thus
reduced survival [92]. The immunosuppressive treatment after liver transplantation is asso‐
ciated with increased risk of tumor recurrence. Thus, immunosuppressant should be re‐
duced to minimum effective levels. Several studies have shown lower recurrence with
sirolimus which is attributed to its anti-proliferative effects on HCC [93-95]. But there is
need for large randomized controlled trials to conclude sirolimus as most appropriate im‐
munosuppressant for patients undergoing liver transplantation for HCC.
3.3. Deceased Donor Liver Transplantation (DDLT)
3.3.1. Graft Allocation
The shortage of donor livers has necessitated the development of allocation system, where‐
by priority for donor organs is given to the most severely ill patients. The prolonged waiting
period frequently results in tumor progression to an extent beyond the transplantable crite‐
ria, leading to a patient's removal or dropout from the waiting list [96]. Allocation of de‐
ceased donor livers for both adults and children is based upon the "model for end stage liver
disease" or MELD score, a statistical model based upon predicted survival in patients with
cirrhosis.As a result of the high dropout rate for patients with HCC, the Organ Procurement
and Transplantation Network (OPTN) of the U.S. has reconsidered the priority of liver graft
allocation. While waiting list priority was determined primarily by liver disease severity
based on the Model for End-Stage Liver Disease (MELD) score, patients with HCC that ful‐
filled the Milan criteria were registered with an adjusted score and were subsequently as‐
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signed additional scores at regular intervals to reflect their risk for dropout as a result of
tumor progression.
3.3.2. Listing Criteria of transplantation candidates
In an attempt to ensure that preoperative assessment is as accurate as possible, UNOS pro‐
vides a set of specific requirements for listing patients with HCC for orthotopic liver trans‐
plantation.
I. The diagnosis must be confirmed by thorough assessment by imaging modalities
such as ultrasound, dynamic CT and /or MRI. Tumor numbers, size, presence or
absence of extrahepatic disease and major vascular disease must be documented.
II. Patient must have one of the following:
1. An Alfa fetoprotein level > 200 ng/mL.
2. Celiac angiography showing tumor blush corresponding to the site shown by
CT/MRI/ultrasonography.
3. A biopsy confirming HCC
4. History of RFA, TACE or other locoregional therapy.
III. Must be within Milan’s criteria.
IV. Continued documentation of the tumor is required every three months by CT or
MRI to ensure continued eligibility for liver transplantation.
Patients will be given priority MELD score depending upon the state of underlying disease.
Prioritization scores for patients with HCC are based upon tumor size and number. With
this new organ allocation policy, waiting time for the patients with HCC to receive a de‐
ceased-donor liver has decreased significantly.
3.4. Living Donor Liver Transplantation (LDLT)
The shortage of organs from deceased donors has curtailed the adoption of living donor liv‐
er transplantation. Living donors can potentially provide an essentially unlimited source of
liver grafts for a planned transplant operation as soon as the diagnosis of HCC is made, thus
decreasing the uncertainty of long waiting periods and reducing possibility of tumor pro‐
gression [97]. The living donor can be from adult-to-adult or adult-to-child. In children
mostly left lateral segment of the liver harvested and donors are usually ABO-compatible
parents. While in adult-to-adult, right or left liver can be harvested that depends upon pre‐
transplant evaluation of donor and CT volumetry of liver. The GRWR (graft to recipient
weight ratio) must be more than 0.8%. Donor not meeting these criteria is rejected for the
fear of small-for-size syndrome and subsequent graft failure [98, 99].
Because a live donor graft is a dedicated gift that is directed exclusively to a particular recip‐
ient, there is no need for an objective allocation system based on a prioritization scheme.
Presently LDLT comprises almost >90% of liver transplants in Asia as compared to <5% in
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US. Unlike in the U.S., where recipients with malignancies receive extra prioritization in the
deceased donor organ allocation scheme, HCC patients in Asia do not. HCC patients in Asia
have a dismal chance of receiving a deceased donor graft and LDLT is often the only option.
3.5. Pretransplant locoregional therapies
Pretransplant locoregional therapy has been adopted by the liver transplant community
worldwide. This concept, known as “bridging therapy” is meant to limit tumor progression
and dropout rate while patients are on the transplant wait list. The most popular techniques
include TACE, transarterial drug-eluting beads, transarterial radio-embolizationand RFA.In
the transplant setting, TACE is currently the most popular neo-adjuvant treatment. It is indi‐
cated in Child–Pugh A or B cirrhotic patients to downstage tumors into the Milan criteria or
to prevent tumor progression. For patients with small HCC confined to the liver, recent data
also indicate that transplantation when used with multimodal therapy using locoregional
procedures and neoadjuvant systemic chemotherapy, results in improved recurrence-free
survival [100, 101]. Apart from that, it is also important to know the wait list dropout rate
and bridging therapy-associated complication rate, because the benefit of preventing wait
list dropout should outweigh the risk of bridging therapy.Patient-individualized treatment
strategy should be based on the performance status, hepatic reserve, tumor burden, and tu‐
mor vascularity pattern.
3.6. Outcome of liver transplantation
To date, orthotopic liver transplantation is no doubt the best therapeutic option for early,
unresectable HCC, although it is limited by graft shortage and the need for appropriate pa‐
tient selection. Since the introduction of the milan’s criteria, the liver transplantation for pri‐
mary HCC is on rise with promising recurrence-free survival and overall survival. Excellent
5-year post-transplant patient survival of at least 70% has been reported from many centers
[102]. Furthermore, better definition of the prognostic factors and more rigorous patient se‐
lection have resulted in significant improvement in 5-year survival for patients receiving
transplants for HCC in the past decade.
However, a tendency for higher HCC recurrence has been reported for patients who under‐
went LDLT than patients who underwent DDLT [103, 104]. The reasons for this difference
are not completely answered by current studies. Possible explanations can be related to the
selection bias for clinical characteristics associated with aggressive tumor behavior, elimina‐
tion of natural selection during the waiting period, and enhancement of tumor growth and
invasiveness by small-for-size graft injury and regeneration [105, 106]. Additionally, more
clinical studies with long-term follow-up are needed to evaluate the role of LDLT for early
HCC. At present, if a suitable and willing donor is identified, LDLT is a reasonable alterna‐
tive to waiting 6 to 12 months for a deceased donor graft in patients with HCC who are oth‐
erwise eligible for liver transplantation.
Although liver transplantation is the only option for the cure in majority of the patients with
HCC complicated by underlying cirrhosis precluding resection, identification of prognostic
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factors and refinement of selection criteria will improve the outcomes of liver transplanta‐
tion for this otherwise fatal disease. Nonetheless, liver transplantation may also pose a risk
of post transplant lymphoproliferative disorders and other de novo malignacy associated
with long term immunosuppression.
4. Conclusion
The management of patients with HCC remains complex and challenging. Although liver
resection and liver transplantation are the curative treatments for HCC at present, there is
considerable controversy as to whether patients with HCC are better served with liver trans‐
plantation versus liver resection. Liver transplantation removes HCC with underlying cir‐
rhosis and thus sounds best option; however, technical challenges associated with
transplantation and/or immunosuppression should be taken into consideration for selecting
transplant cadidates. Currently, most studies suggest that liver resection should be a priori‐
ty in patients who are candidates for either liver resection or transplantation [102, 107]. De‐
spite a better cancer cure rate for liver transplatation, liver resection remains superior for
patients in terms of limited organ availability and transplantation-associated morbidity and
mortality. Therefore, the optimal treatment for patients with preservd liver function should
always be resection whenever the tumor is resectable, and liver transplantation could be re‐
served as a salvage therapy for patients who encounter HCC recurrence after primary liver
resection. Theoretically, this strategy will not only improve patient survival but relieve the
growing demand of available donor livers.
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